Journal Top Ten

photo-5 photo-6 Related Drug: Avandia

Article: Evaluation of Liver Function in Type 2 Diabetic Patients During Clinical Trials: Evidence That Rosiglitazone Does Not Cause Hepatic Dysfunction

Summary: An analysis of liver function in Type 2 diabetic patients at baseline and serially in 13 double-blind, 2 open-label active-controlled, and 7 open-label extension studies of rosiglitazone treatment conducted in outpatient centers throughout North America and Europe. The study comprised more than 6,000 patients agest 30 to 80 years old. Patients underwent liver function studies measuring liver enzyme levels over several months. According to the results, there was no evidence of hepatotoxic effects …